Antibiotics for multidrug-resistant gram-negative bacteria

Background: Increase in antimicrobial-resistant bacteria continues to be challenge physicians. Particularly, multidrug-resistant (MDR) gram-negative bacilli (GNB), such as extended-spectrum beta-lactamase (ESBL)-producers and carbapenem-resistant pathogens, are becoming a major human health problem globally.Current Concepts: Gram-negative have developed resistance via mechanisms encoding AmpC beta-lactamases, ESBLs, carbapenemases. The therapeutic options available for these pathogens extremely limited. Infection by MDR is associated with ineffective antimicrobial therapy, which poses threat the survival of patients serious infections. Physicians should familiar local epidemiology bacterial infections options. Carbapenems considered drugs choice treating ESBL or AmpC-producers. However, increased use carbapenems response an prevalence could rapid emergence carbapenem resistance. Therefore, there ongoing quest carbapenem-sparing regimens treatment MDR-GNB. Treatment MDR-GNB need not limited novel agents now available.Discussion Conclusion: This comprehensive review aims describe Korea, country high pathogens. Recently that urgently introduced Korea include ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol. These been shown effective against Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii.